Compare Incyte Corporation (INCY) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oklo Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Oklo Inc trades at $34.7 (market cap $6.43B). The key difference: Incyte Corporation is far larger — about 3.6× Oklo Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Oklo Inc for 32 Days on average.
| INCY | OKLO | |
|---|---|---|
Market Cap | $22.85B | $6.43B |
Volume | 1,927,029 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $129.93 | $174.14 |
52-Week Low | $83.80 | $34.57 |
Typical Hold Time | 33 Days | 32 Days |
Enterprise Value | $18.35B | $3.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
OKLO trades at $34.57, down 6.11% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strong with 71% buy ratings and a $78.63 price target. Recent news highlights nuclear industry momentum but questions OKLO's commercialization timeline versus established peers.
Outlook hinges on project execution amid substantial cash burn. High institutional financing supports growth but dilution risks persist. The stock offers speculative upside if nuclear contracts materialize, but faces near-term execution and competitive challenges in the small modular reactor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
